María Cambray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
María Cambray has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Victor Moreno
Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), 28029 Madrid, Spain
4 shared publications - Elisabet Guinó
Unit of Biomarkers and Susceptibility, Catalan Institute of Oncology, IDIBELL and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain
3 shared publications - Gabriel Capellá
Hereditary Cancer Program, Catalan Institute of Oncology - ONCOBELL, IDIBELL, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, Madrid, Spain
3 shared publications Matilde Navarro
Institut Catala d'Oncologia, Hospitalet, Barcelona, Spain; and
3 shared publicationsBerta Laquente
Servei d'Oncologia Mèdica, Institut Català d'Oncologia, L'Hospitalet de Llobregat (Barcelona), España
2 shared publications- David Parés
Servicio de Cirugía General y Digestiva, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain
2 shared publications
Latest Publications
- 1 October 2017
- Published by Elsevier in Cirugía Española
- Vol. 95 (8) , 447-456
Experiencia inicial en el tratamiento del adenocarcinoma de páncreas borderline resectable
- 1 October 2017
- Published by Elsevier in Cirugía Española
- Vol. 95 (8) , 447-456
Experiencia inicial en el tratamiento del adenocarcinoma de páncreas borderline resectable
- 1 December 2016
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 42 (12) , 1873-1880
Improving survival and local control in rectal cancer in Catalonia (Spain) in the context of centralisation: A full cycle audit assessment
- 1 December 2016
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 42 (12) , 1873-1880
Improving survival and local control in rectal cancer in Catalonia (Spain) in the context of centralisation: A full cycle audit assessment
- 1 November 2016
- Published by Elsevier in Cirugía Española
- Vol. 94 (9) , 518-524
Resultados de la cirugía de la recidiva pélvica de cáncer de recto. Experiencia en un centro de referencia
- 1 November 2016
- Published by Elsevier in Cirugía Española
- Vol. 94 (9) , 518-524
Resultados de la cirugía de la recidiva pélvica de cáncer de recto. Experiencia en un centro de referencia
- Open Access
- 26 February 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 59
Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer
To evaluate whether the addition of bevacizumab (BVZ) to capecitabine-based chemoradiotherapy in the preoperative treatment of locally advanced rectal cancer (LARC) improves efficacy measured by the pathological complete response (pCR) rate. A phase II two-step design was performed. Patients received four cycles of therapy consisting of: BVZ 10 mg/kg in first infusion on day 1 and 5 mg/kg on days 15, 29, 43, capecitabine 1800 mg/m2/day 5 days per week during radiotherapy, which consisted of external-beam irradiation (45 Gy in 1.8 Gy dose per session over 5 sessions/week for 5 weeks). Six to eight weeks after completion of all therapies surgery was undergone. To profile the biological behaviour during BVZ treatment we measured molecular biomarkers before treatment, during BVZ monotherapy, and during and after combination therapy. Microvessel density (MVD) was measured after surgery. Forty-three patients were assessed and 41 were included in the study. Three patients achieved a pathological complete response (3/40: 7.5%) and 27 (67.5%) had a pathological partial response, (overall pathological response rate of 75%). A further 8 patients (20%) had stable disease, giving a disease control rate of 95%. Downstaging occurred in 31 (31/40: 77.5%) of the patients evaluated. This treatment resulted in an actuarial 4-year disease-free and overall survival of 85.4 and 92.7% respectively. BVZ with chemoradiotherapy showed acceptable toxicity. No correlations were observed between biomarker results and efficacy variables. BVZ with capecitabine and radiotherapy seem safe and active and produce promising survival results in LARC. ClinicalTrials.gov Identifier NCT00847119 . Trial registration date: February 18, 2009.
- 26 February 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 59
Open AccessPhase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer
To evaluate whether the addition of bevacizumab (BVZ) to capecitabine-based chemoradiotherapy in the preoperative treatment of locally advanced rectal cancer (LARC) improves efficacy measured by the pathological complete response (pCR) rate. A phase II two-step design was performed. Patients received four cycles of therapy consisting of: BVZ 10 mg/kg in first infusion on day 1 and 5 mg/kg on days 15, 29, 43, capecitabine 1800 mg/m2/day 5 days per week during radiotherapy, which consisted of external-beam irradiation (45 Gy in 1.8 Gy dose per session over 5 sessions/week for 5 weeks). Six to eight weeks after completion of all therapies surgery was undergone. To profile the biological behaviour during BVZ treatment we measured molecular biomarkers before treatment, during BVZ monotherapy, and during and after combination therapy. Microvessel density (MVD) was measured after surgery. Forty-three patients were assessed and 41 were included in the study. Three patients achieved a pathological complete response (3/40: 7.5%) and 27 (67.5%) had a pathological partial response, (overall pathological response rate of 75%). A further 8 patients (20%) had stable disease, giving a disease control rate of 95%. Downstaging occurred in 31 (31/40: 77.5%) of the patients evaluated. This treatment resulted in an actuarial 4-year disease-free and overall survival of 85.4 and 92.7% respectively. BVZ with chemoradiotherapy showed acceptable toxicity. No correlations were observed between biomarker results and efficacy variables. BVZ with capecitabine and radiotherapy seem safe and active and produce promising survival results in LARC. ClinicalTrials.gov Identifier NCT00847119 . Trial registration date: February 18, 2009.
- 17 February 2012
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 14 (2) , 132-137
Interobserver variability in target volume delineation in postoperative radiochemotherapy for gastric cancer. A pilot prospective study
The aim of this study is to determine the interobserver variability (IV) between radiation oncologists (RO) in target volume delineation for postoperative gastric cancer (GC) radiotherapy planning. Four physicians were asked to delimitate clinical target volume (CTV) on the same 3D CT images in 9 postoperative radiochemotherapy GC patients. Instructions were given to include tumour bed, remaining stomach, anastomosis, duodenal loop and local lymph nodes. The principal variable was spatial volume discrepancy between the main observer (called “A”) and other observers (all called “B”), which were compared using the mathematical formula A∪B/A∩B, applied to the 3D CT images using Boolean operators. Analysis of variance with two random effects (observers and patients) was performed. Mean volumes were 1410 cm3 for OBA, 1231 cm3 for OB2, 734.6 cm3 for OB3 and 1350 cm3 for OB4. Discrepancies were 519.9±431.6 cm3 for OB2, 652.1±294.36 cm3 for OB3 and 225.90±237.07 cm3 for OB4. Standard deviation ascribed to patients as random effect was 898.6 cm3 and that ascribed to observers was 198.10 cm3, considered as a statistically significant difference. A significant IV in target delineation that can be attributed to many factors depends more on patients’ characteristics than RO delineating decisions.
- 17 February 2012
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 14 (2) , 132-137
Interobserver variability in target volume delineation in postoperative radiochemotherapy for gastric cancer. A pilot prospective study
The aim of this study is to determine the interobserver variability (IV) between radiation oncologists (RO) in target volume delineation for postoperative gastric cancer (GC) radiotherapy planning. Four physicians were asked to delimitate clinical target volume (CTV) on the same 3D CT images in 9 postoperative radiochemotherapy GC patients. Instructions were given to include tumour bed, remaining stomach, anastomosis, duodenal loop and local lymph nodes. The principal variable was spatial volume discrepancy between the main observer (called “A”) and other observers (all called “B”), which were compared using the mathematical formula A∪B/A∩B, applied to the 3D CT images using Boolean operators. Analysis of variance with two random effects (observers and patients) was performed. Mean volumes were 1410 cm3 for OBA, 1231 cm3 for OB2, 734.6 cm3 for OB3 and 1350 cm3 for OB4. Discrepancies were 519.9±431.6 cm3 for OB2, 652.1±294.36 cm3 for OB3 and 225.90±237.07 cm3 for OB4. Standard deviation ascribed to patients as random effect was 898.6 cm3 and that ascribed to observers was 198.10 cm3, considered as a statistically significant difference. A significant IV in target delineation that can be attributed to many factors depends more on patients’ characteristics than RO delineating decisions.
- 31 July 2011
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 13 (7) , 472-479
Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy
Objectives The aim of this study was to retrospectively evaluate clinical characteristics, local control, acute and late toxicity, and prognostic factors of patients with anal canal carcinoma treated with brachytherapy. Methods From 1989 to 2009, 38 patients were treated with iridium 192 low-dose-rate (N=26) or pulsed-dose-rate (N=12) interstitial brachytherapy at a single institution. The median age was 62 years (range, 38–86 years). The TNM classification was as follows: 10 T1, 22 T2, 5 T3 and 1 T4; 32 N0, 3 N1 and 3 N2. Most patients (32/38) received either a first course of radiochemotherapy (N=22) or radiotherapy alone (N=10) consisting of a total delivered dose of 45 Gy to the pelvis (range, 32–50) followed by a boost a median of 18 days later of 15–35 Gy (median 20 Gy) to the anal canal. The remaining 6 cases were treated with brachytherapy alone (dose range, 60–65 Gy). Results With a median follow-up of 30 months (range, 4–200), 2- and 5-year local control rates were 91% and 87%, respectively. Preservation of the anal sphincter was achieved in 32 patients (84%). Three patients experienced incontinence after brachytherapy. Only 2 patients showed chronic mucositis grade 3/4. Age proved to be a statistically significant prognostic factor for overall survival in the univariate (p=0.033) and multivariate analyses (p=0.018). Concurrent chemotherapy with external beam radiotherapy was a statistically significant prognostic factor for disease-free survival in the univariate and multivariate analyses (p=0.007 and p=0.044, respectively). Conclusions Interstitial brachytherapy appears to be an effective and well tolerated treatment for anal carcinoma offering both high local tumour control and anal sphincter preservation.
- 31 July 2011
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 13 (7) , 472-479
Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy
Objectives The aim of this study was to retrospectively evaluate clinical characteristics, local control, acute and late toxicity, and prognostic factors of patients with anal canal carcinoma treated with brachytherapy. Methods From 1989 to 2009, 38 patients were treated with iridium 192 low-dose-rate (N=26) or pulsed-dose-rate (N=12) interstitial brachytherapy at a single institution. The median age was 62 years (range, 38–86 years). The TNM classification was as follows: 10 T1, 22 T2, 5 T3 and 1 T4; 32 N0, 3 N1 and 3 N2. Most patients (32/38) received either a first course of radiochemotherapy (N=22) or radiotherapy alone (N=10) consisting of a total delivered dose of 45 Gy to the pelvis (range, 32–50) followed by a boost a median of 18 days later of 15–35 Gy (median 20 Gy) to the anal canal. The remaining 6 cases were treated with brachytherapy alone (dose range, 60–65 Gy). Results With a median follow-up of 30 months (range, 4–200), 2- and 5-year local control rates were 91% and 87%, respectively. Preservation of the anal sphincter was achieved in 32 patients (84%). Three patients experienced incontinence after brachytherapy. Only 2 patients showed chronic mucositis grade 3/4. Age proved to be a statistically significant prognostic factor for overall survival in the univariate (p=0.033) and multivariate analyses (p=0.018). Concurrent chemotherapy with external beam radiotherapy was a statistically significant prognostic factor for disease-free survival in the univariate and multivariate analyses (p=0.007 and p=0.044, respectively). Conclusions Interstitial brachytherapy appears to be an effective and well tolerated treatment for anal carcinoma offering both high local tumour control and anal sphincter preservation.
- 1 December 2010
- Published by Elsevier in Cirugía Española
- Vol. 88 (6) , 374-382
Tratamiento quirúrgico del adenocarcinoma pancreático mediante duodenopancreatectomía cefálica (parte 2). Seguimiento a largo plazo tras 204 casos
- 1 December 2010
- Published by Elsevier in Cirugía Española
- Vol. 88 (6) , 374-382
Tratamiento quirúrgico del adenocarcinoma pancreático mediante duodenopancreatectomía cefálica (parte 2). Seguimiento a largo plazo tras 204 casos
- 1 March 2007
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 9 (3) , 183-191
Preoperative radio-chemotherapy (RT-CT) in rectal cancer. Prospective study with postoperative RT-CT control group.
- 1 March 2007
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 9 (3) , 183-191
Preoperative radio-chemotherapy (RT-CT) in rectal cancer. Prospective study with postoperative RT-CT control group.
- Open Access
- 24 October 2006
- Published by Springer Nature in Journal of Negative Results in BioMedicine
- Vol. 5 (1) , 15
Polymorphisms within inflammatory genes and colorectal cancer
Chronic inflammation is a risk factor for colorectal cancer and polymorphisms in the inflammatory genes could modulate the levels of inflammation. We have investigated ten single nucleotide polymorphisms (SNPs) in the following inflammation-related genes: TLR4 (Asp299Gly), CD14 (-260 T>C), MCP1 (-2518 A>G), IL12A (+7506 A>T, +8707 A>G, +9177 T>A, +9508 G>A), NOS2A (+524T>C), TNF (-857C>T), and PTGS1 (V444I) in 377 colorectal (CRC) cancer cases and 326 controls from Barcelona (Spain). There was no statistically significant association between the SNPs investigated and colorectal cancer risk. The lack of association may show that the inflammatory genes selected for this study are not involved in the carcinogenic process of colorectum. Alternatively, the negative results may derive from no particular biological effect of the analysed polymorphisms in relation to CRC. Otherwise, the eventual biological effect is so little to go undetected, unless analysing a much larger sample size.
- 24 October 2006
- Published by Springer Nature in Journal of Negative Results in BioMedicine
- Vol. 5 (1) , 15
Open AccessPolymorphisms within inflammatory genes and colorectal cancer
Chronic inflammation is a risk factor for colorectal cancer and polymorphisms in the inflammatory genes could modulate the levels of inflammation. We have investigated ten single nucleotide polymorphisms (SNPs) in the following inflammation-related genes: TLR4 (Asp299Gly), CD14 (-260 T>C), MCP1 (-2518 A>G), IL12A (+7506 A>T, +8707 A>G, +9177 T>A, +9508 G>A), NOS2A (+524T>C), TNF (-857C>T), and PTGS1 (V444I) in 377 colorectal (CRC) cancer cases and 326 controls from Barcelona (Spain). There was no statistically significant association between the SNPs investigated and colorectal cancer risk. The lack of association may show that the inflammatory genes selected for this study are not involved in the carcinogenic process of colorectum. Alternatively, the negative results may derive from no particular biological effect of the analysed polymorphisms in relation to CRC. Otherwise, the eventual biological effect is so little to go undetected, unless analysing a much larger sample size.